Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00839527 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 685
- Enrollment target
NCT00839527 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 685 participants.
The verdict
NCT00839527, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 685 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
Interventions
- DRUG metformin
- DRUG pioglitazone
- BIOLOGICAL albiglutide
- DRUG glimepiride
- DRUG placebo to match albiglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 685 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00839527
The ClinicalTrials.gov registry entry for NCT00839527 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 685 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which metformin is the first listed.
NCT00839527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00839527 about?
NCT00839527 is a clinical study titled "A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes". The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
What is the current status of trial NCT00839527?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 685 participants. The study started on 2009-02. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00839527?
The interventions under investigation include: metformin (DRUG), pioglitazone (DRUG), albiglutide (BIOLOGICAL), glimepiride (DRUG), placebo to match albiglutide (DRUG).
Who is sponsoring clinical trial NCT00839527?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.